HK1137931A1 - 長期 小時經腸給予左旋多巴/卡比多巴 - Google Patents

長期 小時經腸給予左旋多巴/卡比多巴

Info

Publication number
HK1137931A1
HK1137931A1 HK10103896.7A HK10103896A HK1137931A1 HK 1137931 A1 HK1137931 A1 HK 1137931A1 HK 10103896 A HK10103896 A HK 10103896A HK 1137931 A1 HK1137931 A1 HK 1137931A1
Authority
HK
Hong Kong
Prior art keywords
carbidopa
levodopa
long term
intestinal administration
hour
Prior art date
Application number
HK10103896.7A
Other languages
English (en)
Inventor
‧尼霍姆
‧阿斯伯格
‧博爾蘇伊
‧圖奇克-塞特勒
Original Assignee
雅培產品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 雅培產品有限公司 filed Critical 雅培產品有限公司
Publication of HK1137931A1 publication Critical patent/HK1137931A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK10103896.7A 2006-05-31 2010-04-21 長期 小時經腸給予左旋多巴/卡比多巴 HK1137931A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80988906P 2006-05-31 2006-05-31
PCT/EP2007/055275 WO2007138086A1 (en) 2006-05-31 2007-05-31 Long term 24 hour intestinal administration of levodopa/carbidopa

Publications (1)

Publication Number Publication Date
HK1137931A1 true HK1137931A1 (zh) 2010-08-13

Family

ID=38434843

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103896.7A HK1137931A1 (zh) 2006-05-31 2010-04-21 長期 小時經腸給予左旋多巴/卡比多巴

Country Status (16)

Country Link
US (1) US20080051459A1 (zh)
EP (1) EP2063865A1 (zh)
JP (1) JP2009543761A (zh)
KR (1) KR20090057349A (zh)
CN (1) CN101636145B (zh)
AU (1) AU2007267135B2 (zh)
BR (1) BRPI0711882A2 (zh)
CA (1) CA2653683A1 (zh)
HK (1) HK1137931A1 (zh)
IL (1) IL195599A0 (zh)
MX (1) MX2008015339A (zh)
NO (1) NO20085418L (zh)
RU (1) RU2484815C2 (zh)
UA (1) UA95954C2 (zh)
WO (1) WO2007138086A1 (zh)
ZA (1) ZA200810834B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2714112C (en) 2008-02-06 2015-08-11 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
DK2432454T3 (en) * 2009-05-19 2017-06-19 Neuroderm Ltd COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA DECARBOXYLASE INHIBITORS
CN110123743A (zh) * 2010-11-15 2019-08-16 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US10335540B2 (en) 2012-04-17 2019-07-02 Micrel Medical Devices S.A. Pharmaceutical blend infusion thereof and Parkinson's disease monitoring system
DK2854764T3 (en) 2012-06-05 2019-04-08 Neuroderm Ltd COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HRP20231716T1 (hr) 2014-03-13 2024-03-15 Neuroderm Ltd. Pripravci inhibitora dopa dekarboksilaze
DK3782617T3 (da) 2014-09-04 2024-03-04 Lobsor Pharmaceuticals Ab Farmaceutiske gelsammensætninger omfattende levodopa, carbidopa og entacapon
CN111454290B (zh) 2014-10-21 2022-12-23 艾伯维公司 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
AU2017299710A1 (en) * 2016-07-20 2019-01-31 Abbvie Inc. Levodopa and carbidopa intestinal gel and methods of use
EA036784B1 (ru) 2016-08-18 2020-12-21 Илько Илач Санайи Ве Тиджарет Аноним Ширкети Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона
EP3758754A1 (en) 2018-03-02 2021-01-06 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
CN118121710A (zh) 2018-03-23 2024-06-04 劳波索尔制药有限公司 用于治疗神经退行性疾病的药物组合物的连续施用
WO2019191353A1 (en) * 2018-03-29 2019-10-03 Riverside Pharmaceuticals Corporation Levodopa fractionated dose composition and use
US11389398B2 (en) 2019-05-14 2022-07-19 Clexio Biosciences Ltd. Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
WO2023126945A1 (en) * 2022-01-03 2023-07-06 Neuroderm, Ltd. Methods and compositions for treating parkinson's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
CA2412490A1 (en) * 2000-06-23 2002-01-03 Moshe Fleshner-Barak Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
CN101023056B (zh) * 2004-06-04 2011-05-25 克塞诺波特公司 左旋多巴前药、和组合物及其应用
EP1811975A2 (en) * 2004-10-19 2007-08-01 The State of Oregon Acting by and Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions

Also Published As

Publication number Publication date
CN101636145A (zh) 2010-01-27
IL195599A0 (en) 2009-09-01
CA2653683A1 (en) 2007-12-06
NO20085418L (no) 2009-02-26
WO2007138086A1 (en) 2007-12-06
RU2484815C2 (ru) 2013-06-20
MX2008015339A (es) 2008-12-16
US20080051459A1 (en) 2008-02-28
CN101636145B (zh) 2014-04-23
EP2063865A1 (en) 2009-06-03
JP2009543761A (ja) 2009-12-10
UA95954C2 (ru) 2011-09-26
ZA200810834B (en) 2010-03-31
BRPI0711882A2 (pt) 2012-01-10
AU2007267135A1 (en) 2007-12-06
AU2007267135B2 (en) 2013-03-07
KR20090057349A (ko) 2009-06-05
RU2008150776A (ru) 2010-07-10

Similar Documents

Publication Publication Date Title
HK1137931A1 (zh) 長期 小時經腸給予左旋多巴/卡比多巴
IL175314A0 (en) Administration of levodopa and carbidopa
IL186684A0 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
EP1987068A4 (en) MODIFICATION OF OLIGOSACCHARIDES AND MARKING OF PROTEINS
EP2104424A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
EP1924318A4 (en) SYNCHRONIZATION OF REPETITIVE THERAPEUTIC INTERVENTIONS
GB0604535D0 (en) Betulonic acid derivatives
HK1128477A1 (zh) 甘草次酸衍生物
PL1994004T3 (pl) 1,4-Dipodstawione pochodne 3-cyjano-pirydonu i ich zastosowanie jako pozytywnych allosterycznych modulatorów receptorów MGLUR2
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
IL193473A0 (en) Amide derivatives and their application for the treatment of g protein related diseases
IL180650A (en) Levodopa solution for infusion and injection
GB2436421B (en) Timing source
WO2011044230A9 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
HRP20130544T1 (en) Long term treatment of hiv- infection with tcm278
GB0622834D0 (en) Timing source
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
IL194189A0 (en) Combination treatment of metabolic disorders
IL193687A0 (en) Formulations of sitaxsentan sodium
ZA200800348B (en) Derivatives of seleno-amino acids
GB0602780D0 (en) Amino Acid Derivatives
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
IL187732A0 (en) Levodopa compositions
GB0601688D0 (en) Cuff fasteners